LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Lachlan Hanbury Brown has maintained a Buy rating on LENZ Therapeutics due to its commercial progress and the launch of the "Make it VIZZable" campaign, which aims to educate presbyopic patients. The campaign's digital strategy is expected to enhance patient acquisition. Hanbury Brown views the early launch as a sign of strong physician adoption and anticipates significant long-term revenue growth from LENZ's differentiated product profile. Citi also supports this view with a Buy rating and a $52 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments